Dexmedetomidine Improves the Surgical Field and Postoperative Recovery of Nasal Endoscopic Surgery

• Status: Completed
• Trial end date: 2020-03-10
• Target enrollment: 0
• Participant gender: All

Summary

Studies showed dexmedetomidine (DEX) could improve surgical field, but the effect for functional nasal endoscopic surgery (FESS) was unclear. The investigators explored IV administration of a single loading dose DEX (0.5μg/kg) for FESS, and IV administration of midazolam (0.05mg/kg) as a control with comparision of surgical field, haemodynamics, ventilation parameters and recovery.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Eye & ENT Hospital of Fudan University
• Treatments: Dexmedetomidine; Midazolam

Criteria

Inclusion Criteria:

• 120 participants who diagnosed with nasosinusitis

• The participants need undergo functional nasal endoscopic surgery

• The participants signed the informed consent

Exclusion Criteria:

• The participants were excluded with any diseases about respiration, circulation, liver and kidney

• The participants were rejected of the consent